title: Brain-derived tumor necrosis factor-alpha and its involvement in noradrenergic neuron functioning involved in the mechanism of action of an antidepressant.
abstract: The present study documents a role for brain-derived tumor necrosis factor-alpha (TNF) in the mechanism of action of the antidepressant drug desmethylimipramine (desipramine). To establish this role, field stimulation and superfusion of rat hippocampal slices was employed to investigate the regulation of norepinephrine (NE) release by TNF. Chronic desipramine administration transforms TNF-mediated inhibition of NE release to facilitation, dependent upon alpha2-adrenergic receptor activation. Chronic i.c.v. microinfusion of polyclonal TNF antibody (pTNF-Ab) similarly transforms TNF inhibition of NE release to facilitation. To determine whether this transformation is due to desipramine-induced inhibition of TNF bioactivity in the brain, rats were i.c.v. microinfused with recombinant rat TNF (rrTNF) for 14 days, either alone or with simultaneous i.p. desipramine administration. TNF regulation of NE release in hippocampal slices isolated from these rats was compared with slices isolated from rats chronically administered desipramine alone. Although simultaneous microinfusion of rrTNF with chronic desipramine administration prevents the transformation induced by desipramine, microinfusion of rrTNF enhances TNF inhibition of NE release. These cellular events correspond to changes in immobility, analyzed by the forced swim test (FST). Intracerebroventricular microinfusion of rrTNF increases the duration of immobility of rats in the FST, compared with rats microinfused with aCSF. Desipramine administered chronically decreases immobility duration, which is mimicked by i.c.v. microinfusion of pTNF-Ab and prevented by simultaneous i.c.v. microinfusion of rrTNF. Thus, i.c.v. microinfusion of rrTNF with concomitant desipramine administration opposes decreases in neuron-associated TNF levels, required to transform presynaptic sensitivity to TNF, which is necessary for the drug to be efficacious.
authors.affiliation: University at Buffalo, The State University of New York, Department of Pathology and Anatomical Sciences, 206 Farber Hall, 3435 Main Street, Buffalo, New York 14214, USA.
authors.forename: Jessica L
authors.initials: JL
authors.lastname: Reynolds
authors.forename: Tracey A
authors.initials: TA
authors.lastname: Ignatowski
authors.forename: Reeteka
authors.initials: R
authors.lastname: Sud
authors.forename: Robert N
authors.initials: RN
authors.lastname: Spengler
mesh_terms: D000818:Animals; D000928:Antidepressive Agents; D001921:Brain / Q000378:metabolism*; D008297:Male; D009474:Neurons / Q000378:metabolism / Q000502:physiology*; D009638:Norepinephrine / Q000378:metabolism*; D017729:Presynaptic Terminals / Q000502:physiology; D051381:Rats; D017207:Rats, Sprague-Dawley; D013997:Time Factors; D014316:Tritium; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism / Q000494:pharmacology*
chemical_list: D000928:Antidepressive Agents; D014409:Tumor Necrosis Factor-alpha; D014316:Tritium; D009638:Norepinephrine